Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vyvanse in Moderate to Severe Binge Eating Disorder
NCT01718483Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2012
- Primary completion
- Sep 2013
- Countries
- 4
01
Overview
A Phase 3 trial of lisdexamfetamine in binge eating disorder (BED), sponsored by Takeda. Started Nov 2012; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on NCT01718483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01718483.